Log in to save to my catalogue

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in pati...

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in pati...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2474173241

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

About this item

Full title

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2021-01, Vol.22 (1), p.142-154

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundImproved therapeutic options are needed for patients with relapsed or relapsed and refractory multiple myeloma. Subcutaneous bortezomib has replaced intravenous bortezomib as it is associated with a more favourable toxicity profile. We investigated the activity and safety of three different dosing regimens of oral panobinostat in c...

Alternative Titles

Full title

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2474173241

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2474173241

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(20)30680-X

How to access this item